Monitor subsequent Form 4 filings to confirm execution. This small insider sale is unlikely to move the stock. No change to investment thesis given strong analyst consensus.
BCRX drugs
BCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $9.60entry
- T+1 · 6mo ago −0.31%α −1.09% · $9.57
- T+5 · 6mo ago −8.96%α −8.82% · $8.74
- T+20 · 5mo ago −11.46%α −10.85% · $8.50
- T+60 · 3mo ago −2.29%α −6.73% · $9.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Officer Alane P. Barnes filed a Form 144 indicating intent to sell 62,500 shares of BioCryst Pharmaceuticals (BCRX), valued at approximately $596,250. The shares are from an option grant dated 2017. Given the relatively small size relative to market cap ($2.2B) and no apparent negative catalyst, the filing is routine.
Key Facts
- Reporting person: Alane P. Barnes (Officer)
- Proposed sale: 62,500 shares of common stock
- Estimated value: $596,250 (based on filing date price)
- Shares acquired via option granted on 12/20/2017
- Sale intended for cash; filed on 05/13/2026
Financial Impact
Approximately $596,250, representing ~0.027% of market cap
Risk Factors
- Potential for larger unannounced insider sales if this is part of a planned selling program
- No specific risk from this filing alone
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-003553 |
| Document: 0001959173-26-003553-index.html | 0001959173-26-003553 |
| Document: 0001959173-26-003553.txt | 0001959173-26-003553 |
Track record
20 reports on BCRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers